Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?

International Journal of Gynecological Cancer

Volumn 22, Issue 5, 2012, Pages 762-769

  Ferriss, James Stuart ^a   Ring, Kari ^a   King, Erin R ^a   Courtney Brooks, Madeleine ^a   Duska, Linda R ^a   Taylor, Peyton T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Epithelial ovarian cancer; Medical comorbidities; Neoadjuvant chemotherapy

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BLEEDING; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; EMBOLISM; FALLOPIAN TUBE CANCER; FEMALE; GROUPS BY AGE; GYNECOLOGIC CANCER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTENSIVE CARE UNIT; INTESTINE RESECTION; LIVER DISEASE; LIVER RESECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MEDICAL COMORBIDITY; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; POSTOPERATIVE THROMBOSIS; PRESURGICAL EMBOLISM; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REOPERATION; RISK ASSESSMENT; SPLENECTOMY; STOMA; STROKE; THROMBOEMBOLISM; TRANSFUSION; ULTRAVIOLET A RADIATION; VENOUS THROMBOEMBOLISM;

CA-125 ANTIGEN; COMORBIDITY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84863665557     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31824b403d     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol. 1971;37:1-9.
3. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
4. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979;63:235-240. (Pubitemid 9151508)
5. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259. (Pubitemid 34177431)
6. Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol. 2010;119:18-21.
7. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
8. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2003; 13:163-168. (Pubitemid 38228759)
9. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105:211-217. (Pubitemid 46441463)
10. Obesity and Overweight for Professionals: Data and Statistics: US Obesity Trends|DNPAO | CDC Available at: http://www.cdc.gov/obesity/data/trends.html. Accessed December 28, 2011.
11. Everett EN, French AE, Stone RL, et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol. 2006;195:568-574; discussion 74-76. (Pubitemid 44142391)
12. Aletti GD, Dowdy SC, Podratz KC, et al. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007; 105:84-89. (Pubitemid 46441445)
13. Geisler JP, Linnemeier GC, Thomas AJ, et al. Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2007;106:128-131. (Pubitemid 46898580)
14. Alphs HH, Zahurak ML, Bristow RE, et al. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol. 2006;103:1048-1053. (Pubitemid 44821333)
15. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94: 650-654. (Pubitemid 39194456)
16. Aletti GD, Gostout BS, Podratz KC, et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:33-37. (Pubitemid 41815046)
17. Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783-788. (Pubitemid 16060038)
18. Chi DS, Ramirez PT, Teitcher JB, et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol. 2007;25: 4946-4951. (Pubitemid 350220426)